Unique Industry Case Studies and the Industrial Evolution of Lowell, Massachusetts

To fully contextualize the application of modern R&D tax incentives, one must understand the unique industrial geography of Lowell, Massachusetts. Located at the confluence of the Merrimack and Concord Rivers, Lowell is universally recognized as the “Cradle of the American Industrial Revolution”. Founded in the 1820s as a planned manufacturing center by the Boston Associates—inspired by Francis Cabot Lowell’s reverse-engineering of British power looms—the city pioneered large-scale, vertically integrated manufacturing in the United States. Utilizing an intricate network of waterpower canals dug by immigrant labor, Lowell’s massive brick mill complexes dominated global textile production for a century.

However, following capital flight to the American South and overseas in the mid-20th century, the city entered a protracted economic depression. In the 1970s and 1980s, Lowell experienced a “second wave” of growth driven by the minicomputer industry, anchored by Wang Laboratories. When Wang collapsed in the early 1990s, the city was forced to pivot once more. Today, Lowell is in the midst of a highly successful “third wave” of economic revitalization, transitioning from traditional manufacturing to a highly diversified, deep-technology R&D hub. Driven by the University of Massachusetts Lowell (UMass Lowell), historic mill infrastructure has been repurposed into state-of-the-art laboratory spaces, supported by initiatives like the Hamilton Canal Innovation District (HCID) and the $800 million Lowell Innovation Network Corridor (LINC).

The following five case studies examine specific industries that have established roots in this revitalized ecosystem, detailing how enterprises within these sectors can leverage federal and Massachusetts R&D tax frameworks.

Medical Device Engineering and Prototyping

Historical Development in Lowell: The medical device cluster in Lowell is a direct outgrowth of deliberate state investment and academic partnership, designed to replace the void left by legacy manufacturing. In 2006, the Massachusetts Medical Device Development Center (M2D2) was established as a joint venture between UMass Lowell—leveraging its globally recognized Plastics Engineering department and advanced manufacturing capabilities—and UMass Medical School in Worcester, which provided clinical expertise. By 2010, utilizing capital from the Massachusetts Life Sciences Center (MLSC), M2D2 expanded into the historic Wannalancit Mills complex and later to 110 Canal Street, providing startups with affordable wet lab space, access to 3D printing cores, and a supportive ecosystem to bridge the “valley of death” between concept and commercialization.

Industry Example & R&D Activities: EnVision Endoscopy, an M2D2 resident company, is developing novel image-guided suturing systems (IGSS) for gastrointestinal endoscopic surgery. Their R&D focuses on creating single-use, disposable attachments for standard flexible endoscopes to facilitate tissue approximation and manage gastrointestinal defects, reducing the need for invasive surgeries. This involves intense mechanical engineering, biomaterials testing, and iterative prototyping of catheter and blade mechanisms.

Application of Federal and State Tax Laws:

• Federal IRC Section 41: The mechanical engineering and iterative prototyping of the suturing catheter directly meet the federal four-part test for qualified research. However, the enterprise must rigorously document its “process of experimentation.” To satisfy the standards established by the Tax Court in Siemer Milling Co. v. Commissioner, the firm cannot rely on generalized assertions of uncertainty. It must retain detailed CAD models, tensile stress-test logs on biomaterials, and documented failure analyses proving that alternatives were evaluated scientifically to achieve the optimal blade rotation and suture capture mechanisms.
• Massachusetts M.G.L. c. 63, § 38W: Because EnVision is engaged in the life sciences sector, it is eligible for certification by the MLSC. Under M.G.L. c. 63, § 38W (the Life Sciences Research Credit), the company can claim 10% of its qualified research expenses (QREs), specifically including expenses for legally mandated clinical trials conducted outside of Massachusetts. This is a massive advantage over the standard Section 38M credit, which strictly requires all research to be physically conducted within state lines. Furthermore, as an early-stage company operating at a net loss, the MLSC can authorize a refund of up to 90% of the § 38W credit balance, providing critical non-dilutive capital directly back into their R&D pipeline.

Industrial Robotics and Automation Systems

Historical Development in Lowell: Lowell’s modern robotics industry inherits the foundational DNA of the 19th-century Lowell Machine Shop, which originally fabricated water turbines, textile machinery, and New England’s first steam locomotives. As traditional heavy machinery evolved, the region’s focus shifted to precision instruments and electronics. Today, this legacy is institutionalized within the New England Robotics Validation and Experimentation (NERVE) Center at UMass Lowell. Operating out of repurposed mill space, the NERVE Center functions as the premier robotics testing site in the Northeast, partnering with the National Institute of Standards and Technology (NIST), the U.S. Army, and the Advanced Robotics for Manufacturing (ARM) Institute to develop standardized benchmarking for exoskeletons, autonomous mobile robots, and manipulators.

Industry Example & R&D Activities: Rapid Micro Biosystems, a prominent employer in Lowell, manufactures the Growth Direct® System, which utilizes multi-axis robotic arms and sophisticated digital imaging algorithms to automate microbial quality control testing for pharmaceutical manufacturing. Their R&D involves integrating advanced robotics with autofluorescence imaging to detect microbial colonies without human intervention, eliminating error-prone manual processes.

Application of Federal and State Tax Laws:

• Federal IRC Section 41 and Little Sandy Coal: Developing automated, high-throughput robotic incubators involves significant hardware and software QREs. Robotics R&D requires extensive physical testing, where technicians must build test tracks, calibrate optical sensors, and run thousands of hardware cycles. Under the Seventh Circuit’s recent taxpayer-favorable ruling in Little Sandy Coal Co. v. Commissioner (2023), the wages paid to these technicians for the “direct support” of the lead engineers are explicitly includable in the numerator and denominator of the 80% “substantially all” calculation, validating the inclusion of these massive labor costs in the final QRE pool.
• Massachusetts Local and State Incentives: As an advanced manufacturer, the firm benefits from overlapping state and municipal incentives. The City of Lowell offers a highly specific Research and Development Personal Property Tax Exemption, providing a 100% local tax exemption on core equipment (e.g., servers, lab equipment, robotic CNC machinery) directly related to R&D activities. At the state level, the firm can utilize the M.G.L. c. 63, § 38M research credit to offset 100% of its first $25,000 in corporate excise tax, plus 75% of any liability exceeding that amount, carrying forward any unused credits indefinitely.

Advanced Functional Fabrics and Smart Textiles

Historical Development in Lowell: While Lowell’s foundational identity is rooted in the 19th-century textile boom, traditional cotton and wool manufacturing has long been obsolete. The city’s textile heritage has been deliberately resurrected through high-technology innovation. In 2018, supported by state funding and national manufacturing institutes, UMass Lowell opened the Fabric Discovery Center (FDC) at 110 Canal Street. The FDC is the first facility in the nation to integrate resources from three Manufacturing USA institutes: AFFOA (Advanced Functional Fabrics of America), NextFlex (Flexible Hybrid Electronics), and ARM (Robotics). This infrastructure allows companies to transition ideas from fiber synthesis to wearable microelectronics.

Industry Example & R&D Activities: Tandem Repeat Technologies, which maintains an R&D presence in Lowell, utilizes synthetic biology to create sustainable, non-polluting protein-based fibers known as Squitex. Their research involves scaling upstream bioprocesses to improve biomass yield, extracting and purifying recombinant proteins, and optimizing the wet-spinning of these novel fibers to achieve unique stretch and self-healing properties intended to replace traditional petrochemical textiles.

Application of Federal and State Tax Laws:

• Federal IRC Section 41 (Supply QREs): Developing synthetic protein fibers requires extensive chemical and biological experimentation. Supply costs in biotechnology are heavily scrutinized by tax authorities. To qualify under IRC Section 41(b)(2)(C), the raw materials, reagents, and precursor chemicals used in the genetic engineering and wet-spinning processes must be consumed directly in the conduct of qualified research, and cannot be capitalized or subject to depreciation.
• Massachusetts M.G.L. c. 63, § 38M (The ASM Election): Massachusetts strictly enforces the physical location rule; only supplies consumed and wages prorated for days worked specifically at the Lowell laboratory are eligible for the state calculation. Because Tandem Repeat is a rapidly scaling company with fluctuating historic gross receipts, calculating the credit using the traditional fixed-base methodology is administratively burdensome. Instead, the company would optimally elect the Alternative Simplified Method (ASM) under 830 CMR 63.38M.2(8). This allows the firm to claim a credit equal to 10% of its current year Massachusetts QREs that exceed 50% of its average QREs over the prior three years, rewarding rapid, localized expansion in research expenditures.

Aerospace, SmallSats, and Space Technology

Historical Development in Lowell: The aerospace cluster represents Lowell’s newest industrial frontier. Following the departure of legacy defense contractors, the city leveraged academic capital to build a new space tech ecosystem. Supported by a $5.5 million collaborative R&D matching grant from MassTech in 2023, the Massachusetts Alliance for Space Technology and Sciences (MASTS) consortium was launched at the Lowell Center for Space Science and Technology (LoCSST). Located at the Wannalancit Business Center, LoCSST provides a centralized hub for academia and deep-tech startups to design, fabricate, and environmentally test miniature satellites (CubeSats) and optical sensors. The talent pipeline from UMass Lowell’s aerospace engineering programs, coupled with successful NASA satellite deployments like the SPACE HAUC mission, has firmly anchored this high-growth industry in the city.

Industry Example & R&D Activities: Startups operating within the MASTS consortium focus on the development of advanced imaging optics, high-frequency communication antennas, radiation-hardened materials, and navigation systems for nanosatellites and satellite constellations.

Application of Federal and State Tax Laws:

• Federal IRC Section 41 and the Funded Research Exclusion: Aerospace R&D startups frequently build proprietary components under contract for prime defense contractors or federal agencies. They face significant legal hurdles regarding the IRC Section 41(d)(4)(H) “funded research” exclusion. Applying the legal standards affirmed in Meyer, Borgman & Johnson, Inc. v. Commissioner (2024), an aerospace firm must meticulously structure its commercial contracts. If a startup operates under a fixed-price contract to deliver a satellite component, but the contract lacks explicit language making the payment strictly contingent upon the successful resolution of technological uncertainty (e.g., if they are paid for passing design milestones regardless of ultimate functionality), the IRS will deem the research “funded” by the client and fully disallow the credit. The startup must also retain substantial rights to the underlying intellectual property.
• Massachusetts Defense-Related Activity Apportionment: At the state level, the firm can utilize unique statutory mechanisms. Under M.G.L. c. 63, § 38M, the aerospace firm can elect to calculate its credit specifically based on “defense-related activities” (which statutorily includes equipment developed for NASA), allowing the taxpayer to isolate these specific QREs and gross receipts from other commercial activities to optimize the credit yield.

Preclinical Biotechnology and Computational Therapeutics

Historical Development in Lowell: Biotechnology development in Lowell has been catalyzed by the intersection of higher education workforce initiatives and aggressive state funding. The Massachusetts Life Sciences Center (MLSC) has continuously poured capital into local infrastructure, funding Biosafety Level 2 (BSL-2) wet labs and specialized cell culture laboratories. In 2021, the MLSC provided a targeted $750,000 investment specifically for Lowell-based life science firms, providing non-dilutive capital via convertible notes. Recently, the Lowell Innovation Network Corridor (LINC) partnered with Bioversity to launch a dedicated life sciences workforce training center within the Wannalancit Mills complex, ensuring a localized, highly trained pipeline of laboratory operations talent.

Industry Example & R&D Activities: Decoy Therapeutics is a preclinical stage biotechnology company headquartered in Lowell that builds pandemic preparedness platforms. Their R&D leverages machine learning (ML) and artificial intelligence (AI) alongside high-speed synthesis techniques to computationally design and engineer peptide conjugate drug candidates—specifically broad-acting antivirals that directly interfere with viral replication machinery for pathogens like COVID-19 and RSV.

Application of Federal and State Tax Laws:

• Federal IRC Section 174A Expensing (OBBBA 2025): A preclinical biotech firm utilizing machine learning for drug design faces massive upfront computational and laboratory expenditures long before clinical revenue is generated. Prior to 2025, the TCJA required firms to capitalize and amortize their domestic preclinical and software R&E costs over five years, severely restricting operational cash flow. The enactment of the “One Big Beautiful Bill Act” (OBBBA) of 2025 is transformative for this sector. For tax years beginning in 2025, under the new IRC Section 174A, Decoy Therapeutics can immediately expense these domestic R&E costs, providing immediate tax relief and preserving vital capital.
• Federal Form 6765 Section G Compliance: When filing the federal return, a complex therapeutic pipeline presents immediate compliance challenges. Under the newly mandatory Section G reporting requirements for Form 6765, the firm cannot aggregate its R&D efforts; it must list the development of a Pan-Coronavirus inhibitor and an RSV antiviral as distinct business components. The firm must allocate specific wages, biological supply costs, and computing resources (e.g., cloud server costs for AI modeling) to each respective project line to survive IRS scrutiny.

Detailed Analysis of United States Federal R&D Tax Credit Requirements

The federal Research and Development tax credit, codified under Internal Revenue Code (IRC) Section 41, is a central pillar of United States economic policy, designed to incentivize businesses to incur the financial risks associated with technological innovation. Structurally, the credit provides a dollar-for-dollar reduction in a taxpayer’s federal income tax liability based on a percentage of qualified research expenses (QREs) that exceed a statutorily defined base amount.

The Section 41 Four-Part Test for Qualified Research

To successfully claim the Section 41 credit, a taxpayer must bear the burden of proving that its R&D activities satisfy a rigorous, conjunctive four-part test. Crucially, these tests must be applied separately to each distinct “business component”—defined by statute as a product, process, computer software, technique, formula, or invention that is held for sale, lease, or license, or used by the taxpayer in a trade or business.

1. The Section 174 Test (Permitted Purpose): The expenditures claimed must be eligible for treatment as research and experimental (R&E) expenses under IRC Section 174. This requires that the activity be undertaken to discover information that would eliminate uncertainty concerning the development or improvement of a business component. The overarching purpose must relate to achieving a new or improved function, performance, reliability, or quality. The statute explicitly dictates that the process of experimentation cannot relate to style, taste, cosmetic, or seasonal design factors.
2. The Technological in Nature Test: The research must fundamentally rely on principles of the hard sciences. Specifically, the innovation must be rooted in physical or biological sciences, engineering, or computer science. Knowledge derived from economics, business management, or behavioral sciences does not qualify.
3. The Elimination of Uncertainty Test: The taxpayer must establish that, at the outset of the project, there was genuine technological uncertainty regarding the capability to develop the component, the methodology required to develop it, or the appropriate design of the component. Uncertainty exists if the information available to the taxpayer does not establish the precise method to achieve the desired result.
4. The Process of Experimentation Test: Substantially all of the activities must constitute elements of a process of experimentation. The IRS defines “substantially all” as 80 percent or more of the research activities measured on a cost or alternative reasonable basis. This requires the taxpayer to systematically identify the technological uncertainty, identify one or more alternatives intended to eliminate that uncertainty, and conduct a process of evaluating those alternatives through modeling, simulation, or systematic trial and error.

Statutory Exclusions from Qualified Research

IRC Section 41(d)(4) expressly enumerates several categories of activities that are excluded from credit eligibility, regardless of whether they appear to meet the four-part test. These exclusions include:

• Research after Commercial Production: Any research conducted after a business component has met its basic functional and economic requirements and is ready for commercial sale or use.
• Adaptation and Duplication: Research related to adapting an existing business component to a particular customer’s specific needs, or reverse-engineering/duplicating an existing product.
• Routine Data Collection and Quality Control: Standard testing or inspections for quality control of regular production runs.
• Foreign Research: Any research conducted outside the United States, the Commonwealth of Puerto Rico, or any possession of the United States.
• Funded Research: Any research funded by a grant, contract, or otherwise by another person or governmental entity. Research is considered funded if the taxpayer’s compensation is not contingent upon the successful completion of the research, or if the taxpayer does not retain substantial rights to the intellectual property generated.

Legislative Evolution: Section 174 Amortization vs. Section 174A Expensing

The financial utility of the IRC Section 41 credit is inextricably linked to the tax treatment of the underlying R&E expenses. Historically, taxpayers were permitted to immediately deduct R&E expenses in the year they were incurred. However, the Tax Cuts and Jobs Act (TCJA) of 2017 mandated a severe capitalization regime. For tax years beginning after December 31, 2021, taxpayers were required to capitalize specified research or experimental (SRE) expenditures and amortize them over five years for domestic research and 15 years for foreign research. This substantially increased the current-year tax burden for innovative companies.

In a pivotal legislative reversal, the enactment of Public Law 119-21, widely known as the “One Big Beautiful Bill Act” (OBBBA) of 2025, introduced a new IRC Section 174A. This provision restores the immediate deduction of domestic research and experimental expenditures for tax years beginning after December 31, 2024. Under Section 174A, taxpayers may deduct these domestic costs immediately, or affirmatively elect to amortize them over a period of not less than 60 months (or 10 years in certain circumstances).

Crucially, the OBBBA and the corresponding Rev. Proc. 2025-28 provide specific transition rules for the unamortized costs trapped from the 2022-2024 period. “Eligible small businesses”—defined as having average annual gross receipts of $31 million or less—are permitted to retroactively apply the expensing rules to 2022-2024 by amending their prior returns. Larger businesses, which do not qualify for retroactive relief, may elect to accelerate the deduction of their remaining unamortized domestic R&E costs evenly over the 2025 and 2026 tax years. Notably, foreign R&E expenses remain excluded from this relief and must continue to be capitalized and amortized over 15 years.

Administrative Guidance: The 2025 Form 6765 Overhaul

The Internal Revenue Service has aggressively increased substantiation requirements to combat what it perceives as inflated R&D claims. The finalized Form 6765 (Credit for Increasing Research Activities), released in February 2025, forces taxpayers to transition from aggregated cost reporting to a granular, project-based methodology.

The most substantial and burdensome addition is Section G (Business Component Information). This section requires detailed qualitative and quantitative disclosures for every individual R&D project. Taxpayers must list each business component, describe the specific information sought to be discovered, detail the alternatives evaluated in the process of experimentation, and provide the exact dollar amount of wages, supplies, and contract expenses allocated to that specific component. Furthermore, for software projects, taxpayers must navigate detailed categorizations distinguishing between internal-use, non-internal use, and dual-function software.

While the IRS made Section G optional for the 2024 tax year, it is strictly mandatory for tax years beginning in 2025. The only exemptions to the Section G reporting requirement are for Qualified Small Businesses (QSBs) that elect to claim the reduced payroll tax credit, and taxpayers who have both total QREs equal to or less than $1.5 million and gross receipts equal to or less than $50 million. Additionally, the new Form 6765 mandates the disclosure of the amount of officers’ wages included in the claim, aimed at identifying unreasonable executive compensation allocations.

Federal Jurisprudence and Tax Court Case Law

Recent decisions from the United States Tax Court and federal appellate circuits have heavily refined the boundaries of the R&D credit. These rulings provide essential guidance on how the IRS interprets the statutory requirements during an examination.

Little Sandy Coal Co. v. Commissioner (2023)

In Little Sandy Coal Co. v. Commissioner, the Seventh Circuit Court of Appeals issued a complex ruling that affirmed the disallowance of the taxpayer’s credits but simultaneously corrected a major legal error by the Tax Court that was hostile to manufacturers. The taxpayer, a shipbuilding company, claimed credits for the development of 11 first-in-class vessels. The dispute centered on the “substantially all” requirement of the process of experimentation test.

The Tax Court had previously ruled that wages for employees engaged in “direct support” and “direct supervision” of research could not be counted as activities constituting a process of experimentation, placing them in the denominator of the 80% fraction but never the numerator. This interpretation mathematically crippled manufacturing claims. The Seventh Circuit rejected this premise, establishing that costs associated with direct support and direct supervision do qualify for inclusion in both the numerator and the denominator, provided the costs qualify as Section 174 expenses. Ultimately, however, the appellate court ruled against Little Sandy Coal because the company failed to provide a principled method for time-tracking, relying instead on arbitrary estimates and the broad assertion of product “novelty,” which the court ruled is not a proper heuristic for the substantially all test.

Suder v. Commissioner (2014)

Suder v. Commissioner remains the definitive precedent regarding the documentation of uncertainty and the limits of executive wage allocations. The taxpayer, Estech Systems, Inc. (ESI), claimed credits for developing telecommunications hardware. The IRS aggressively challenged both the qualification of the projects and the wages of the CEO, Eric Suder, who allocated 75% of his time to R&D.

The Tax Court delivered a significant victory for the taxpayer regarding project qualification, affirming that a business does not have to “reinvent the wheel” to satisfy the elimination of uncertainty test. Uncertainty exists even if a company knows a goal is technically possible, so long as it is uncertain of the optimal method or appropriate design to reach that goal. The court also validated the use of a third-party R&D study that utilized estimated time allocations, because those estimates were heavily corroborated by credible employee testimony. However, the court ruled against the taxpayer on the issue of executive compensation. It found that the CEO’s multimillion-dollar salary was vastly disproportionate to his actual R&D role and standard industry benchmarks, forcing a severe reduction of his eligible wage base under the Section 174 reasonableness standard.

Siemer Milling Co. v. Commissioner (2019)

In Siemer Milling, an Illinois-based wheat flour milling company claimed credits for product and process improvements. The Tax Court completely disallowed the claims, focusing entirely on substantiation failures regarding the process of experimentation. The court acknowledged that the taxpayer engaged in technical activities, but ruled that merely reciting the sequential steps taken to develop a product is legally insufficient. The taxpayer failed to provide technical documents, test logs, design iterations, or proof that they formulated a hypothesis and conducted systematic trial and error to evaluate alternatives. This case cemented the requirement that contemporaneous scientific documentation is mandatory.

Phoenix Design Group (2024) and Meyer, Borgman & Johnson (2024)

Two recent 2024 cases highlight the IRS’s narrowing interpretations of the statute. In Phoenix Design Group, Inc. v. Commissioner, an engineering firm lost its claim because it failed to identify specific technological uncertainties prior to beginning the research. The Tax Court ruled that generalized uncertainty regarding expected design challenges does not satisfy the statutory requirement; uncertainties must be specifically defined at the outset.

In Meyer, Borgman & Johnson, Inc. v. Commissioner, the Eighth Circuit affirmed the disallowance of credits for a structural engineering firm operating under fixed-fee contracts. Historically, taxpayers and practitioners operated under the assumption that fixed-fee contracts inherently placed the economic risk on the taxpayer, thereby satisfying the requirement that payment be “contingent on success” and avoiding the funded research exclusion. However, the courts have shifted to examining strict contractual language. The Eighth Circuit ruled that if a contract does not expressly state by clear implication that payment is contingent upon the successful resolution of specific technical research, the research is legally “funded” by the client and is therefore ineligible for the credit.

Detailed Analysis of Massachusetts State R&D Tax Credit Laws

The Commonwealth of Massachusetts offers a sophisticated R&D tax incentive under Massachusetts General Laws (M.G.L.) Chapter 63, Section 38M. Designed to closely mirror the federal IRC Section 41, the state credit is a vital tool for economic development, aimed at fostering deep-tech innovation and maintaining the state’s competitive edge in the life sciences and advanced manufacturing sectors.

Statutory Mechanics and the Strict Geographic Limitation

Under M.G.L. c. 63, § 38M, business corporations subject to the state corporate excise tax can claim a nonrefundable credit equal to the sum of 10% of the incremental qualified research expenses over a base amount, plus 15% of basic research payments (typically payments to academic or scientific institutions).

The defining characteristic of the Massachusetts credit is its rigorous geographic restriction. The credit applies exclusively to expenditures for research activity physically conducted within the Commonwealth of Massachusetts. If wages are paid to an employee who performs research both inside and outside the state, the eligible wages must be strictly prorated based on the ratio of the number of days the employee worked in Massachusetts to the total days employed in research. Similarly, amounts paid for supplies or computer leases are only eligible to the extent that the tangible property is used or consumed at a research facility physically located within the state.

The Alternative Simplified Method (ASM) and Utilization Caps

To alleviate the administrative burden of calculating the traditional fixed-base percentage—which often requires substantiating gross receipts from the 1980s—Massachusetts introduced the Alternative Simplified Method (ASM) for tax years beginning on or after January 1, 2015. Regulated under 830 CMR 63.38M.2, the ASM allows corporations to calculate their credit based on recent expenditure history. For calendar years beginning on or after January 1, 2021, the ASM credit is equal to 10% of the excess of Massachusetts QREs for the current taxable year over 50% of the corporation’s average QREs for the three preceding taxable years.

The utilization of the generated credit is subject to specific statutory caps designed to ensure a baseline of corporate tax revenue. The credit cannot reduce a corporation’s excise tax liability below the statutory minimum tax of $456. Furthermore, the credit is limited by the “25/75 rule”: a taxpayer may use the credit to offset 100% of its first $25,000 of corporate excise liability, but can only offset 75% of any excise liability that exceeds $25,000. Unused credits generally carry forward for 15 years; however, credits that are specifically disallowed from current-year use due to the 75% limitation rule may be carried forward indefinitely.

M.G.L. c. 63, § 38W: The Life Sciences Research Credit

Recognizing the unique, capital-intensive nature of biotechnology development, Massachusetts enacted M.G.L. c. 63, § 38W as part of the Massachusetts Life Sciences Act. This statute provides a distinct corporate excise tax credit equal to 10% of QREs specifically for certified life sciences companies. The critical advantage of Section 38W is that it explicitly incentivizes legally mandated clinical trial expenditures incurred both inside and outside the Commonwealth, effectively bypassing the strict geographic limitations of Section 38M for clinical data gathering.

Furthermore, to assist pre-revenue startups, the Massachusetts Life Sciences Center (MLSC) possesses the statutory authority to make both the § 38M and § 38W credits refundable. If an eligible, certified life sciences company operates at a net loss and cannot utilize the credit against tax liability, the MLSC can authorize a direct cash refund of 90% of the credit balance, requiring the taxpayer to forfeit the remaining 10% and the associated carryforward provisions.

Massachusetts Administrative Guidance and Appellate Case Law

The Massachusetts Department of Revenue (DOR) continually refines the application of the state R&D tax credit through Technical Information Releases (TIRs) and responses to Appellate Tax Board (ATB) litigation.

TIR 25-5: The Economic Development Act Expansions

In 2025, the DOR issued TIR 25-5 to explain significant updates to corporate tax credits resulting from the Economic Development Act of 2024. This legislation dramatically expanded the scope of state-level R&D incentives:

• Medical Countermeasures Expansion: Under M.G.L. c. 63, § 38M(b)(1), taxpayers can elect to calculate the credit separately for “defense-related activities.” Historically limited to arms and NASA equipment, the 2024 Act expanded this definition to include medical countermeasures. This encompasses R&D on medicines, biologics, vaccines, diagnostic tests, and personal protective equipment used to diagnose, prevent, or treat diseases related to chemical, biological, radiological, or nuclear threats.
• The Climatetech Tax Incentive: The legislation created a parallel incentive program for the green energy sector. Administered by the Massachusetts Clean Energy Technology Center, certified climatetech companies can now access an identical 10% incremental credit and 15% basic research credit for qualified activities, subject to a $30 million annual statewide cap.
• Life Sciences Cap Increase: The cumulative annual amount of tax incentives that the MLSC is authorized to award was increased from $30 million to $40 million, and the definition of eligible “life sciences” was broadened to include biosecurity, artificial intelligence applications, and preventative medicine.

The State Street Corp. Appellate Tax Board Decision and TIR 25-3

In August 2024, the Massachusetts Appellate Tax Board delivered a decisive ruling in State Street Corp. v. Commissioner of Revenue (A.T.B. Docket No. C344139). State Street, operating as a bank holding company and financial institution, claimed over $13 million in Massachusetts research credits generated by its affiliates. The Commissioner of Revenue aggressively audited the claims and denied the credits entirely, arguing that financial institutions, which are subject to tax under M.G.L. c. 63, § 2, were statutorily ineligible. The DOR asserted that the credit was reserved strictly for traditional “business corporations” taxed under M.G.L. c. 63, § 39.

The ATB granted summary judgment in favor of the taxpayer. The Board ruled that the plain and unambiguous language of the law did not limit credit eligibility based on the type of business corporation, and therefore, financial institutions and bank holding companies were fully entitled to seek and claim the Section 38M research credits.

In response to this defeat, the Department of Revenue issued TIR 25-3 in May 2025. This release officially conceded the state’s position, declaring that “all business corporations subject to an excise under M.G.L. c. 63 are allowed to claim the M.G.L. c. 63, § 38M research credit,” explicitly including financial institutions. Furthermore, recognizing that the decision would prompt widespread amended filings from the banking sector, the DOR announced it would relax its regulatory posture and allow taxpayers to retroactively elect the Alternative Simplified Method (ASM) on amended returns and abatement applications, overriding previous regulations that required the ASM to be elected on an original return.

Final Thoughts

The intersection of federal and state R&D tax policy represents a highly lucrative, yet administratively unforgiving, terrain for innovative enterprises. As demonstrated by the industrial evolution of Lowell, Massachusetts, targeted economic development—from the construction of textile canals in the 1820s to the funding of BSL-2 laboratories and robotics testing centers in the 2020s—creates fertile ecosystems where R&D thrives. To legally capitalize on these capital investments, taxpayers must navigate the stringent documentation standards established by federal case law such as Siemer Milling and Meyer, Borgman & Johnson. They must adapt to the new immediate expensing provisions of the 2025 OBBBA (Section 174A) and comply with the granular, component-level reporting requirements of the newly overhauled Form 6765.

At the state level, Massachusetts’ specialized provisions for life sciences refundability, defense-related countermeasure activities, and the newly established Climatetech credit—bolstered by the ATB’s expansion of eligibility in the State Street decision—ensure that companies conducting physical research within the Commonwealth have access to some of the most aggressive, innovation-friendly tax policies in the nation.

The information in this study is current as of the date of publication, and is provided for information purposes only. Although we do our absolute best in our attempts to avoid errors, we cannot guarantee that errors are not present in this study. Please contact a Swanson Reed member of staff, or seek independent legal advice to further understand how this information applies to your circumstances.